Chardan Capital Markets analyst, Madhu Kumar, reiterated his Buy rating on shares of Regulus Therapeutics (NASDAQ: RGLS) and cut his ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE